Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy

Authors

  • Mohammadali Mohammadzadeh Rezaei Masshad University of Medical Sciences
  • Mohammadhadi Mohammadzadeh Rezaei
  • Alireza Ghoreifi Mashhad University of Medical Sciences
  • Behzad Feyzzadeh Kerigh

DOI:

https://doi.org/10.5489/cuaj.3655

Abstract

Introduction: The presence of metabolic syndrome in men with prostate cancer (PCa) undergoing androgen-deprivation therapy (ADT), especially intermittent type, has not been completely evaluated. The aim of this study is to evaluate metabolic syndrome in men with PCa undergoing intermittent ADT.

Methods: In this longitudinal study, we studied the prevalence of metabolic syndrome and its components in 190 patients who were undergoing intermittent ADT. The metabolic syndrome was defined according to the Adult Treatment Panel III criteria. All metabolic parameters, including lipid profile, blood glucose, blood pressures, and waist circumferences of the patients were measured six and 12 months after treatment.

Results: Mean age of the patients was 67.5 ± 6.74 years. The incidence of metabolic syndrome after six and 12 months was 6.8% and 14.7%, respectively. Analysis of various components of the metabolic syndrome revealed that patients had significantly higher overall prevalence of hyperglycemia, abdominal obesity, and hypertriglyceridemia in their six- and 12-month followups, but blood pressure has not been changed in the same period except for diastolic blood pressure after six months.

Conclusions: Although there was an increased risk of metabolic syndrome in patients receiving intermittent ADT, it was lower than other studies that treated the same patients with continuous ADT. Also it seems that intermittent ADT has less metabolic complications than continuous ADT and could be used as a safe alternative in patients with advanced and metastatic PCa.

Downloads

Download data is not yet available.

Author Biographies

Mohammadali Mohammadzadeh Rezaei, Masshad University of Medical Sciences

Department of Urology, Associate Professor

Alireza Ghoreifi, Mashhad University of Medical Sciences

Department of Urology, Assistant Professor

Downloads

Published

2016-09-13

How to Cite

Mohammadzadeh Rezaei, M., Mohammadzadeh Rezaei, M., Ghoreifi, A., & Feyzzadeh Kerigh, B. (2016). Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy. Canadian Urological Association Journal, 10(9-10), E300–05. https://doi.org/10.5489/cuaj.3655

Issue

Section

Original Research